Applied Biological Materials (abm)

Founded in 2004, Applied Biological Materials (abm) develops research reagents, cellular models and genetic engineering tools that support life sciences research and drug discovery. Based in Canada, the company provides capabilities spanning molecular biology, cell biology and functional genomics, enabling researchers to investigate gene function, cellular mechanisms and disease biology. Its expertise includes CRISPR technologies, viral vector systems, gene delivery platforms, recombinant DNA tools, PCR and qPCR reagents, as well as custom research services. These technologies support applications across cancer research, neuroscience, drug development, regenerative medicine, gene expression studies and cell-based assay development.

abm’s portfolio includes lentiviral, adeno-associated viral (AAV) and adenoviral vectors, CRISPR expression systems and knockout resources, siRNA and miRNA tools, expression-ready libraries, antibodies, proteins, growth factors, immortalized and stable cell lines, primary cells, organoid and 3D culture platforms, and nucleic acid purification products. The company also offers custom services covering gene synthesis, cloning, genome editing, recombinant virus production, antibody engineering and cell line development. Together, these products and services support workflows from target identification and functional validation through to advanced cell culture and gene delivery studies.